Recombinant Human LGALS3 (C-6His)

Product Overview

• Article Name: Recombinant Human LGALS3 (C-6His)
• Biozol Catalog Number: EBT-EPT190
• Supplier Catalog Number: EPT190
• Alternative Catalog Number: EBT-EPT190-50
• Manufacturer: ELK Biotechnology
• Category: Proteine/Peptide
• Alternative Names: Galectin-3, Gal-3, 35 kDa Lectin, Carbohydrate-Binding Protein 35, CBP 35, Galactose-Specific Lectin 3, Galactoside-Binding Protein, GALBP, IgE-Binding Protein, L-31, Laminin-Binding Protein, Lectin L-29, Mac-2 Antigen, LGALS3, MAC2

Product Description

Recombinant Human Galectin-3 is produced by our Mammalian expression system and the target gene encoding Ala2-Ile250 is expressed with a 6His tag at the C-terminus.

Product Properties

• Molecular Weight: Molecular weight: 27.2 KDa. Apparent molecular weight: 35 KDa, reducing conditions
• UniProt: AAH53667.1
• Purity: Greater than 95% as determined by reducing SDS-PAGE.

Application Notes

• Application Notes: Redissolve: Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100µg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.. Endotoxin: Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test. Background: Galectin-3(LGALS3) is also known as Galactose-specific lectin 3, Mac-2 antigen, Carbohydrate-binding protein 35, Laminin-binding protein and Galactoside-binding protein. LGALS3 is highly expressed in early stages of papillary carcinoma, and lowly during tumor progression. LGALS3 is probably forms homo- or heterodimers and secreted by a non-classical secretory pathway and associates with the cell surface. LGALS3 plays an important role during the acquisition of vasculogenic mimicry and angiogenic properties. LGLAS3 takes part in an immune regulator to inhibit T-cell immune responses and promote tumor growth, as a result providing a new mechanism for tumor immune tolerance